tetano
Editor, Senior Moderator
J Eur Acad Dermatol Venereol. 2020 Apr 17. doi: 10.1111/jdv.16491. [Epub ahead of print]
Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
Di Altobrando A[SUP]1[/SUP], Patrizi A[SUP]1[/SUP], Bardazzi F[SUP]1[/SUP].
Author information
Abstract
In this dramatic period where the whole world is affected by the outbreak of coronavirus disease 19 (COVID-19), scientific data relating to the causative virus SARS-CoV-2 as well as the subsequent therapeutic repercussions on the management of other diseases should be divulged in order to share as much information as possible among experts in a timely manner.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; SARS-CoV-2; blistering disorders; bullous disorders; immunosuppressive therapy
PMID:32302437DOI:10.1111/jdv.16491
Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
Di Altobrando A[SUP]1[/SUP], Patrizi A[SUP]1[/SUP], Bardazzi F[SUP]1[/SUP].
Author information
Abstract
In this dramatic period where the whole world is affected by the outbreak of coronavirus disease 19 (COVID-19), scientific data relating to the causative virus SARS-CoV-2 as well as the subsequent therapeutic repercussions on the management of other diseases should be divulged in order to share as much information as possible among experts in a timely manner.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; SARS-CoV-2; blistering disorders; bullous disorders; immunosuppressive therapy
PMID:32302437DOI:10.1111/jdv.16491